GPX4 and non-small cell lung carcinoma: Bufotalin (BT), a novel GPX4 inhibitor, increases the degradation of GPX4 and intracellular Fe2+ level, causing ferroptosis in non-small cell lung cancer cells (Zhang et al. 2022b).